• Technology
  • Applications
    • AML MRD
    • Mutagenesis
    • Cellular Immunotherapy
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
    • Investors
  • Contact
TwinStrand Biosciences
  • Technology
  • Applications
    • AML MRD
    • Mutagenesis
    • Cellular Immunotherapy
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
    • Investors
  • Contact

 

Cellular Immunotherapy Monitoring

 

Monitoring persistence and pharmacokinetics of off-the-shelf or allogeneic cellular immunotherapies, such as chimeric antigen receptor T-cells (CAR-T) and engineered natural killer (NK) cells, is challenging due to the limited accuracy and sensitivity of testing methodologies. Traditional techniques developed for chimerism monitoring in bone marrow and solid organ transplantation simply do not have the sensitivity for immunotherapy monitoring.

 

The extraordinary sensitivity of TwinStrand Duplex Sequencing™ technology makes it possible to detect allogeneic cells below one-in-one-million frequency.

Analytical Sensitivity Below One-in-One-Million

As a measure of technical performance, allogeneic CAR-T DNA was serially diluted into control DNA at ratios from 1/300 to 1/1.1 million. Deep Duplex Sequencing was carried out on all samples in triplicate using a panel of 277 polymorphic SNP sites. Measured frequencies vs. expected frequencies are shown below with 95% confidence intervals.

Measured versus Expected CAR-T Fraction

 

Allogeneic CAR-T DNA was detected at the expected frequencies in all spike-ins down to below one-in-one-million. No allogeneic CAR-T DNA was detected in the negative control demonstrating unprecedented sensitivity and specificity.

TwinStrand Duplex Sequencing is the Most Sensitive Chimerism Detection Method

 

The accuracy of TwinStrand Duplex Sequencing technology provides the highest level of sensitivity for the detection of chimerism of any existing technology. In addition, because of the multi-locus nature of the Duplex Sequencing assay, it requires less DNA input than ddPCR at lower levels of sensitivity.

 

Figure reference: Limits of detection shown in the figure are based on published ranges for current chimerism detection methods. Abbreviations: STR CE – Short Tandem Repeat Capillary Electrophoresis, NGS – Next-Generation Sequencing, SNP – Single Nucleotide Polymorphism, qPCR – quantitative polymerase chain reaction, ddPCR – Droplet Digital polymerase chain reaction.

Monitoring CAR-T Cells In Vivo

To demonstrate clinical utility, the same Duplex Sequencing assay was applied to a series of longitudinally collected peripheral blood samples from two patients treated with an allogeneic CAR-T cell therapy. The fraction of CAR-T cells present in blood over time is shown as the blue and green lines. The dashed line indicates the sensitivity threshold of other available technologies.

 

 

Duplex Sequencing reveals complex cell therapy dynamics in these patients over time. The CAR-T abundance in both subjects fell below the detection limit of all other methods within one week of treatment. Subject 1 saw CAR-T levels drop to nearly 1/1,000,000 before rebounding thirty-fold at the 1-month time point, where it persisted for at least six months. Subject 2 saw drug-product levels drop below 1/100,000 within 2 weeks of treatment, where they remained for the duration of the 2-month sampling window.

 

Variation in the kinetics and absolute level of drug product likely correlates with clinical outcome, yet even being able to study this association has been impossible until the introduction of Duplex Sequencing methods.

 

Have questions about Duplex Sequencing for Cellular Immunotherapy?

Contact us

Scientific Content

 

 


Posters

POSTER: Ultra-Sensitive Duplex Sequencing for Tracking of Allogeneic Cell Therapies

POSTER: Ultra-Sensitive Duplex Sequencing for Tracking of Allogeneic Cell Therapies

 


Abstracts

 

Ultra-Sensitive Duplex Sequencing for Quantifying Multi-Individual
Cell Therapy Sub-Population Fractions

 

TwinStrand Biosciences, Inc.
3131 Elliott Ave, Suite 750 • Seattle, WA 98121 • USA
+1 (877) 202-TWIN

 

For Research Use Only. Not for use in diagnostic procedures.

©2022 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners.  Legal Notices

  

American Society of Hematology (ASH)

December 5-8, 2020 – Virtual

 

Poster Presentation

 

“Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia”

 

Presented by Jake Higgins, Senior Scientist – December 6, 2020 7:00 a.m.-3:30 p.m. PST

 

Conference Website

 

Society of Toxicology (SOT)

March 10-14, 2019 – Baltimore, MD

 

Poster Presentations

 

 

View Poster

 

 

Conference Website

 

AACR Annual Meeting – San Diego, CA

March 29-April 3, 2019

 

Poster Presentations

 

 

View Poster

 

 

View Poster

Presentations by CEO Jesse Salk, MD, PhD – AGBT 2020

Ultra-Sensitive Residual Leukemia Detection with Patient-Specific Dupex Sequencing